By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Opsona Therapeutics Ltd. 

The O'Reilly Institute
Trinity College Dublin
Dublin    2  Ireland
Phone: n/a Fax: 353-1-679-8039



Company News
Opsona Therapeutics Ltd. Raises an Additional $4 Million Series C From Omnes Capital 10/2/2013 7:10:30 AM
Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function 5/7/2013 11:19:59 AM
Opsona Therapeutics Ltd. Raises $43 Million to Develop Lead Product 4/29/2013 6:56:26 AM
Opsona Therapeutics Ltd. Announces the Issuance of New Patent From the European Patent Office (EPO) Covering the Development and Use of an Antibody Directed Against Toll-like Receptor TLR-2 4/17/2012 10:24:23 AM
Opsona Therapeutics Ltd. Adds 3.3 Million Euro to Series B 5/20/2009 8:13:04 AM
Galapagos NV (GLPG.BR) And Opsona Therapeutics Ltd. Initiate Drug Discovery Collaboration 4/21/2009 12:11:23 PM
Opsona Therapeutics Ltd., CSL Limited (CMXHF.PK) Form Vaccine Adjuvant R&D Collaboration Targeting Infectious Diseases And Oncology 2/23/2009 11:59:18 AM
Opsona Therapeutics Ltd. Closes E18 Million Funding 2/18/2009 7:06:23 AM
Opsona Therapeutics Ltd. Announces A Collaboration With Wyeth (WYE) On Toll-Like Receptors 2/13/2006 1:06:38 PM
Irish Pharma Start-Up Opsona Therapeutics Ltd. Raises $8.3 Million (EUR6.25 Million) Series A10/19/2005 5:12:51 PM